M
Meena Subramanyam
Researcher at Biogen Idec
Publications - 65
Citations - 4356
Meena Subramanyam is an academic researcher from Biogen Idec. The author has contributed to research in topics: Natalizumab & JC virus. The author has an hindex of 25, co-authored 65 publications receiving 4073 citations. Previous affiliations of Meena Subramanyam include Tufts University.
Papers
More filters
Journal ArticleDOI
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Gary Bloomgren,Sandra Richman,Christophe Hotermans,Meena Subramanyam,Susan Goelz,Amy Natarajan,Sophia Lee,Tatiana Plavina,James V. Scanlon,Alfred Sandrock,Carmen Bozic +10 more
TL;DR: Positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalIZumab-treated patients with multiple sclerosis.
Journal ArticleDOI
Anti-JC virus antibodies: implications for PML risk stratification.
Leonid Gorelik,Michaela Lerner,Sarah A. Bixler,Mary Crossman,Brian Schlain,Kenneth Simon,Amy Pace,Anne Cheung,Ling Ling Chen,Melissa Berman,Fairuz Zein,Ewa Wilson,Ted Yednock,Alfred Sandrock,Susan Goelz,Meena Subramanyam +15 more
TL;DR: A study was undertaken to establish an enzyme‐linked immunosorbent assay (ELISA) to detect JC virus (JCV)‐specific antibodies in multiple sclerosis patients, and to evaluate its potential utility for identifying patients at higher or lower risk of developing progressive multifocal leukoencephalopathy (PML).
Journal ArticleDOI
Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy
Tatiana Plavina,Meena Subramanyam,Gary Bloomgren,Sandra Richman,Amy Pace,Sophia Lee,Brian Schlain,Denise Campagnolo,Shibeshih Belachew,Barry Ticho +9 more
TL;DR: This work analyzed whether anti‐JCV antibody levels, measured as index, may further define PML risk in seropositive patients.
Journal ArticleDOI
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.
Gopi Shankar,Steven Arkin,L. Cocea,Viswanath Devanarayan,Susan Kirshner,A. Kromminga,Valerie Quarmby,Susan M. Richards,Christian Schneider,Meena Subramanyam,Steven J. Swanson,Daniela Verthelyi,S. Yim +12 more
TL;DR: Understanding the incidence, kinetics and magnitude of anti-drug antibody (ADA), its neutralizing ability, cross-reactivity with endogenous molecules or other marketed biologic drugs, and related clinical impact may enhance clinical management of patients treated withBiologic drugs.
Journal ArticleDOI
Challenges and approaches for the development of safer immunomodulatory biologics
Jean G. Sathish,Swaminathan Sethu,Marie Christine Bielsky,Lolke de Haan,Neil French,Karthik Govindappa,James D. Green,Christopher E.M. Griffiths,Stephen T. Holgate,David Jones,Ian Kimber,Jonathan G. Moggs,Dean J. Naisbitt,Munir Pirmohamed,Gabriele Reichmann,Jennifer Sims,Meena Subramanyam,Marque Todd,Jan Willem van der Laan,Richard J. Weaver,B. Kevin Park +20 more
TL;DR: The safety issues associated with immunomodulatory biologics are assessed and the current approaches for predicting and mitigating adverse reactions associated with their use are discussed.